Seeing Is Believing
BTAI is currently covered by 7 analysts with an average potential upside of $16.78 (71.51%) backed by displayed 25 price targets and 75 ratings.
Analysts average stock forecasts to be materialized ratio is 53.61% with an average time for these price targets to be met of 69.5 days.
Highest price target for BTAI is 33, Lowest price target is 3, average price target is 18.
Most recent stock forecast was given by ROBYN KARNAUSKAS from TRUIST on 05-Oct-2023. First documented stock forecast 03-May-2018.
Currently, out of the existing stock ratings of BTAI - 2 which are a Sell (5.88%), 26 which are a Buy (76.47%), 6 which are a Hold (17.65%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
1 months 25 days ago
1/1 (100%)
$-12.97 (-35.08%)
27
Buy
11
$8.47 (334.78%)
11
2 months 17 days ago
0/12 (0%)
$33.3 (229.11%)
Hold
4
$0.09 (2.30%)
4
3 months 7 days ago
7/9 (77.78%)
$4.68 (16.79%)
48
Buy
3 months 15 days ago
1/3 (33.33%)
$17.73 (63.94%)
45
Hold
4
$0.09 (2.30%)
13
3 months 15 days ago
6/8 (75%)
$-0.11 (5.42%)
45
What is BTAI (BioXcel Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on BTAI (BioXcel Therapeutics) with a proven track record?
Which analyst has the most public recommendations on BTAI (BioXcel Therapeutics)?
Which analyst is the currently most bullish on BTAI (BioXcel Therapeutics)?
Which analyst is the currently most reserved on BTAI (BioXcel Therapeutics)?